These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29250133)

  • 21. Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
    Majchrzak K; Nelson MH; Bailey SR; Bowers JS; Yu XZ; Rubinstein MP; Himes RA; Paulos CM
    Cancer Immunol Immunother; 2016 Mar; 65(3):247-59. PubMed ID: 26825102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
    Radfar S; Wang Y; Khong HT
    J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
    Grauer OM; Nierkens S; Bennink E; Toonen LW; Boon L; Wesseling P; Sutmuller RP; Adema GJ
    Int J Cancer; 2007 Jul; 121(1):95-105. PubMed ID: 17315190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization.
    Lees CJ; Apostolopoulos V; McKenzie IF
    J Interferon Cytokine Res; 1999 Dec; 19(12):1373-9. PubMed ID: 10638706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions between the immune system and cancer: a brief review of non-spatial mathematical models.
    Eftimie R; Bramson JL; Earn DJ
    Bull Math Biol; 2011 Jan; 73(1):2-32. PubMed ID: 20225137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell augments the antitumor activity of tumor-targeting Salmonella.
    Lee CH; Hsieh JL; Wu CL; Hsu PY; Shiau AL
    Appl Microbiol Biotechnol; 2011 May; 90(4):1381-8. PubMed ID: 21360146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
    Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
    PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
    Ngiow SF; von Scheidt B; Akiba H; Yagita H; Teng MW; Smyth MJ
    Cancer Res; 2011 May; 71(10):3540-51. PubMed ID: 21430066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mathematical model of tumor-immune surveillance.
    Mahasa KJ; Ouifki R; Eladdadi A; Pillis L
    J Theor Biol; 2016 Sep; 404():312-330. PubMed ID: 27317864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo.
    Yu J; Ren X; Cao S; Zhang W; Hao X
    Cancer Biother Radiopharm; 2006 Jun; 21(3):276-84. PubMed ID: 16918305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outstanding antitumor capacity of CD4
    Li T; Wu B; Yang T; Zhang L; Jin K
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188439. PubMed ID: 32980465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.